Fewer major adverse cardiovascular events in type 2 diabetes patients treated with JANUVIA ® (sitagliptin)
6 December 2011 | By MSD
Data presented at the IDF 21st World Diabetes Congress...
List view / Grid view
News
Combination insulin degludec/insulin aspart significantly reduced hypoglycaemia in diabetes patients
6 December 2011 | By Novo Nordisk
Insulin degludec / insulin aspart reduced rates of hypoglycaemia by 58%...
Merck establishes new MSD R&D Asia Headquarters
6 December 2011 | By
Commits $1.5 billion to R&D in China over the next 5 years...
Sanofi reports positive results for once-daily Lyxumia® (lixisenatide) in Combination with Lantus® (insulin glargine) in Type 2 Diabetes
6 December 2011 | By Sanofi
Data from phase III GetGoal Duo 1 study...
Government boost to world leading UK life science industry
5 December 2011 | By http://www.bis.gov.uk/newsroom
Three million at-risk patients to receive hi-tech equipment in the home - part of a series of measures outlined by the Prime Minister today to support the UK’s life sciences industry...
GSK statement in response to the Prime Minister’s speech on life sciences
5 December 2011 | By GlaxoSmithKline
"The Government’s strategy for Life Sciences is a very important next step on the journey..."
Samsung and Biogen Idec announce joint venture to develop, manufacture and market biosimilars
5 December 2011 | By Biogen Idec
Samsung and Biogen Idec announced that they have entered into an agreement to invest $300 million to establish a joint venture to develop, manufacture and market biosimilars...
Study in type 2 diabetes shows low rates of hypoglycaemia and significant improvements in blood glucose control with insulin analogue treatment
5 December 2011 | By Novo Nordisk
New data from the A1chieve® study...
Groundbreaking scientific collaboration gives UK academia access to compounds to advance medical research
5 December 2011 | By AstraZeneca
A wide range of compounds will be made available FOC to UK medical researchers...
Novartis drug Galvus® approved in EU
5 December 2011 | By Novartis
The European Commission has approved Galvus® (vildagliptin) (50 mg once a day) for the treatment of type 2 diabetes patients with moderate or severe renal impairment...
Bristol-Myers Squibb enters clinical collaboration agreement with Tibotec Pharmaceuticals
2 December 2011 | By Bristol-Myers Squibb Company
Phase II combination study in patients chronically infected with Hepatitis C...
Pfizer completes acquisition of Excaliard
2 December 2011 | By Pfizer
Pfizer Inc. have announced that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company...
Novartis highlights advances for patients with cancers and hematological diseases
2 December 2011 | By Novartis
Novartis will showcase more than 160 presentations on data from its robust oncology portfolio...
Boehringer Ingelheim and AVEO announce manufacturing agreement for ficlatuzumab
1 December 2011 | By Boehringer Ingelheim
AVEO & Boehringer Ingelheim enter into an agreement...
Seeing is believing
1 December 2011 | By kdm communications limited
KNF Lab has launched the SC950 wireless vacuum pump system, combining fast and precise vacuum regulation with a flow rate of up to 50 l/min...
